Ø
Øystein Bruserud
Researcher at University of Bergen
Publications - 363
Citations - 9937
Øystein Bruserud is an academic researcher from University of Bergen. The author has contributed to research in topics: Leukemia & Myeloid leukemia. The author has an hindex of 46, co-authored 354 publications receiving 8873 citations. Previous affiliations of Øystein Bruserud include Haukeland University Hospital & SINTEF.
Papers
More filters
Journal ArticleDOI
Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells
Jonathan M. Irish,Randi Hovland,Peter O. Krutzik,Omar D. Perez,Øystein Bruserud,Øystein Bruserud,Bjørn Tore Gjertsen,Bjørn Tore Gjertsen,Garry P. Nolan +8 more
TL;DR: By exposing cancer cell signaling networks to potentiating inputs, rather than relying upon the basal levels of protein phosphorylation alone, it is shown that individual cancers manifested multiple cell subsets with unique network profiles, reflecting cancer heterogeneity at the level of signaling response.
Journal ArticleDOI
SIRT1 Activation by a c-MYC Oncogenic Network Promotes the Maintenance and Drug Resistance of Human FLT3-ITD Acute Myeloid Leukemia Stem Cells
Ling Li,Tereza Osdal,YinWei Ho,Sookhee Chun,Tinisha McDonald,Puneet Agarwal,Allen Lin,Su Chu,Jing Qi,Liang Li,Yao-Te Hsieh,Cedric Dos Santos,Hongfeng Yuan,Trung-Quang Ha,Mihaela Popa,Randi Hovland,Øystein Bruserud,Øystein Bruserud,Bjørn Tore Gjertsen,Bjørn Tore Gjertsen,Ya-Huei Kuo,WenYong Chen,Sonia Lain,Emmet McCormack,Emmet McCormack,Ravi Bhatia +25 more
TL;DR: It is shown that the NAD-dependent SIRT1 deacetylase is selectively overexpressed in primary human FLT3-ITD AML LSCs and contributes to their maintenance.
Journal ArticleDOI
Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells
TL;DR: Divergent effects of HDAC inhibition on the global gene expression profiles have been described when testing various cancer cells, and this is further complicated by altered HDAC expression induced by HDAC inhibitors.
Journal ArticleDOI
Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells.
Øystein Bruserud,Anita Ryningen,Astrid Marta Olsnes,Laila Stordrange,Anne Margrete Øyan,Karl-Henning Kalland,Bjørn Tore Gjertsen +6 more
TL;DR: Differences in chemokine responsiveness as well as Chemokine release contribute to patient heterogeneity in AML.
Journal ArticleDOI
Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities
TL;DR: Intracellular signaling initiated by Flt3 ligation modulates the functional phenotype for native human AML blasts both with and without genetic Flt 3 abnormalities.